The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.
The Prognostic Value of Multiparametric Flow Cytometry in AL Amyloidosis at Diagnosis and at the End of First-Line Treatment
Multiparametric flow cytometry (MFC) in AL amyloidosis has not been widely adopted and consequently there is little information on its clinical relevance. Mayo Clinic researchers studied 173 AL amyloidosis patients who underwent MFC immunophenotyping of bone marrow sample at diagnosis and 82 patients at the end of the first line of treatment (EOT). Based on the study results, researchers found that MFC is prognostic for AL amyloidosis at diagnosis and at the end of treatment. MFC may also have a role in the definition of hematological response. The study was published in Blood.
Published to PubMed This Week
- Sacral Chordoma
Mayo Clinic Proceedings
- DNMT3A Mutations are Associated with Inferior Overall and Leukemia-free Survival in Chronic Myelomonocytic Leukemia
American Journal of Hematology
- Lenalidomide Treatment and Prognostic Markers in Relapsed or Refractory Chronic Lymphocytic Leukemia: Data From the Prospective, Multicenter Phase-II CLL-009 Trial
Blood Cancer Journal
- Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer
Clinical Colorectal Cancer
- Deletion 5q is Frequent in Myelodysplastic Syndrome (MDS) Patients Diagnosed with Interstitial Lung Diseases (ILD): Mayo Clinic Experience
- Carcinoid Heart Disease without Severe Tricuspid Valve Involvement
- Clinical and Therapeutic Relevance of the Metabolic Oncogene Fatty Acid Synthase in HER2+ Breast Cancer
Histology and Histopathology